AU2022265461A1 - Molephantin derivatives useful in the treatment of cancer - Google Patents
Molephantin derivatives useful in the treatment of cancer Download PDFInfo
- Publication number
- AU2022265461A1 AU2022265461A1 AU2022265461A AU2022265461A AU2022265461A1 AU 2022265461 A1 AU2022265461 A1 AU 2022265461A1 AU 2022265461 A AU2022265461 A AU 2022265461A AU 2022265461 A AU2022265461 A AU 2022265461A AU 2022265461 A1 AU2022265461 A1 AU 2022265461A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- alkyl
- substituted
- unsubstituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10202104429U | 2021-04-29 | ||
| SG10202104429U | 2021-04-29 | ||
| PCT/SG2022/050251 WO2022231520A1 (en) | 2021-04-29 | 2022-04-27 | Molephantin derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022265461A1 true AU2022265461A1 (en) | 2023-11-16 |
Family
ID=83848883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022265461A Pending AU2022265461A1 (en) | 2021-04-29 | 2022-04-27 | Molephantin derivatives useful in the treatment of cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250304544A1 (https=) |
| EP (1) | EP4330241A4 (https=) |
| JP (1) | JP2024517443A (https=) |
| CN (1) | CN117377663A (https=) |
| AU (1) | AU2022265461A1 (https=) |
| IL (1) | IL308058A (https=) |
| WO (1) | WO2022231520A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115919833A (zh) * | 2023-01-31 | 2023-04-07 | 暨南大学附属第一医院（广州华侨医院） | 一种CutC蛋白抑制剂及其应用 |
| AU2024337402A1 (en) * | 2023-09-06 | 2026-03-26 | Nanyang Biologics Pte. Ltd. | Collective synthesis of phantomolin family through total synthesis of the sesquiterpene lactone molephantin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3418724B2 (ja) * | 2000-02-10 | 2003-06-23 | 国立医薬品食品衛生研究所長 | セスキテルペノイド化合物及びそれを含む医薬 |
| JP2005002050A (ja) * | 2003-06-12 | 2005-01-06 | Shiseido Co Ltd | 美白剤及びこれを配合した皮膚外用剤 |
| CN102000072A (zh) * | 2009-09-01 | 2011-04-06 | 奇复康药物研发(苏州)有限公司 | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 |
| CN103732586B (zh) * | 2011-04-07 | 2016-02-03 | 南洋理工大学 | 作为抗癌剂的乙酰基丹参酮iia(ata) |
| WO2019040335A1 (en) * | 2017-08-19 | 2019-02-28 | University Of Rochester | MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS |
| CN111153910B (zh) * | 2020-01-09 | 2021-07-30 | 沈阳药科大学 | 地胆草种内酯衍生物及其制备方法和用途 |
-
2022
- 2022-04-27 JP JP2023566885A patent/JP2024517443A/ja active Pending
- 2022-04-27 WO PCT/SG2022/050251 patent/WO2022231520A1/en not_active Ceased
- 2022-04-27 EP EP22796282.6A patent/EP4330241A4/en active Pending
- 2022-04-27 AU AU2022265461A patent/AU2022265461A1/en active Pending
- 2022-04-27 US US18/556,616 patent/US20250304544A1/en active Pending
- 2022-04-27 IL IL308058A patent/IL308058A/en unknown
- 2022-04-27 CN CN202280031592.6A patent/CN117377663A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL308058A (en) | 2023-12-01 |
| JP2024517443A (ja) | 2024-04-22 |
| US20250304544A1 (en) | 2025-10-02 |
| EP4330241A4 (en) | 2025-03-19 |
| EP4330241A1 (en) | 2024-03-06 |
| WO2022231520A1 (en) | 2022-11-03 |
| CN117377663A (zh) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2749096T3 (es) | Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados | |
| TWI564291B (zh) | 一氧化氮生成調節劑 | |
| ES2965675T3 (es) | Antagonistas del receptor NK-3 para el tratamiento terapéutico o cosmético del exceso de grasa corporal | |
| EP3908570B1 (en) | Ketamine pamoate and use thereof | |
| US20250304544A1 (en) | Molephantin derivatives useful in the treatment of cancer | |
| PT94713A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo um derivado heteroaril-3-oxo-propanonitrilico como ingrediente activo capazes de estimular a mielopoese em mamiferos | |
| ES2989515T3 (es) | Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas | |
| AU2017221673B2 (en) | Novel indole derivative and anti-cancer composition containing same | |
| WO2019052477A1 (zh) | 丹参酮类化合物及其用于治疗血管瘤的用途 | |
| CN117136050A (zh) | 用于使用大麻素治疗神经元病症的组合物和方法 | |
| BRPI0718904A2 (pt) | Pirrol[1,2-a] imidazolodiona efetiva no tratamento de neurotoxicidade induzida por agentes quimioterapêuticos | |
| CN116761598A (zh) | Fabp4调节化合物的抗病毒用途 | |
| CN110709079B (zh) | 包含1，2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物 | |
| JP2024510249A (ja) | 神経疾患を治療するための組成物およびその方法 | |
| KR20230061528A (ko) | 구강 건조증의 치료에 사용하기 위한 화합물 | |
| CN106554349A (zh) | 野八角新异戊烯基取代c6‑c3类化合物及其制备方法、应用和其药物组合物 | |
| CN116987091B (zh) | 用于治疗癫痫发作疾病的药物及其制备方法 | |
| CA3118954C (en) | Ketamine pamoate and use thereof | |
| KR100379155B1 (ko) | 새로운 진통제 조성물 | |
| WO2025043213A2 (en) | Therapeutic compounds and methods | |
| CN120936351A (zh) | 任选地与n-酰基乙醇胺组合地包含3,4-亚甲基二氧基甲基苯丙胺的组合物及其用途 | |
| CN118541368A (zh) | 使用bcn057、bcn077及类似物的治疗方法 | |
| AU2015201006A1 (en) | Benzopyran compounds and use thereof | |
| CN117797134A (zh) | 一种4-tmap治疗或缓解抑郁症的用途 | |
| BR112021013340B1 (pt) | Sal de pamoato de cetamina e usos de uma composição farmacêutica compreendendo o referido sal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NANYANG TECHNOLOGICAL UNIVERSITY Free format text: FORMER APPLICANT(S): NANYANG TECHNOLOGICAL UNIVERSITY; NANYANG HERBS PTE. LTD. Owner name: NANYANG BIOLOGICS PTE. LTD. Free format text: FORMER APPLICANT(S): NANYANG TECHNOLOGICAL UNIVERSITY; NANYANG HERBS PTE. LTD. |